

KCMS EQUITY TRACKING TOOL

Monitoring Access and Timeliness in Cervical Cancer Care

Purpose: To help care teams identify and address disparities in treatment access, timeliness, and outcomes for patients with cervical cancer. Use this tool monthly or quarterly to review internal data and drive system-level improvements.

1 Timeliness of Care

METRIC	TARGET	NOTES
Median time from diagnosis → treatment start	≤21 days	Track separately by insurance type (private, Medicaid, Medicare, uninsured)
Median time from recurrence → second-line therapy	≤14 days	Track by biomarker status and geography
% of patients experiencing ≥30-day delay	<10%	Flag and review monthly at tumor board

2 Access and Utilization

METRIC	TARGET	NOTES
% of patients referred to gynecologic oncology	100%	Within 5 days of diagnosis
% of patients with completed biomarker testing (PD-L1, HER2, RET, NTRK, TMB)	≥ 95%	Include community and rural clinics
% of patients offered clinical trial participation	≥ 80%	Track acceptance and decline reasons

3 Equity & Social Determinants

METRIC	TARGET	NOTES
Missed or cancelled appointments due to transportation	↓ over time	Offer telehealth or rideshare vouchers
Patients needing interpreter services	Document 100%	Track language and resource gaps
Average distance to treatment site (miles or travel time)	Variable	Use mapping or zip code analysis
Denials or delays by payer	↓ 25% yr-over-yr	Use PA Toolkit appeal templates

Quality Review

- ✓ Review equity metrics monthly in tumor board or QI meeting.
- ✓ Identify 2-3 actionable steps (e.g., interpreter hiring, ride assistance, workflow redesign).
- ✓ Assign responsibility and follow up quarterly.
- ✓ Share progress across clinical and administrative teams.

✓ Quick Tip

- Integrate this tool into EHR dashboards or Excel trackers.
- Pair with the KCMS Prior Authorization Toolkit and Referral Flowchart to monitor improvements in access and timeliness.

Sources: NCCN Guidelines: Cervical Cancer (2025); CDC Cancer Equity Framework (2024); ASCO Equity & Access Recommendations (2024).